NovoCure Limited (NVCR)
NASDAQ: NVCR · IEX Real-Time Price · USD
18.40
-0.08 (-0.43%)
At close: Jul 19, 2024, 4:00 PM
18.09
-0.31 (-1.68%)
Pre-market: Jul 22, 2024, 7:00 AM EDT
Company Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally.
The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
NovoCure Limited
| Country | Jersey |
| Founded | 2000 |
| IPO Date | Oct 2, 2015 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 1,453 |
| CEO | Asaf Danziger |
Contact Details
Address: No. 4 The Forum, Grenville Street St. Helier, Y9 JE2 4UF Jersey | |
| Phone | 44 (0)15 3475 6700 |
| Website | novocure.com |
Stock Details
| Ticker Symbol | NVCR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001645113 |
| CUSIP Number | G6674U108 |
| ISIN Number | JE00BYSS4X48 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Asaf Danziger | Chief Executive Officer and Director |
| William F. Doyle | Executive Chairman |
| Ashley Cordova | Chief Financial Officer |
| Wilhelmus C. M. Groenhuysen | Chief Operating Officer |
| Frank Leonard | Executive Vice President and President of Novocure Oncology |
| Prof. Yoram Palti M.D., Ph.D. | Founder and Chief Technology Officer |
| Dr. Moshe Giladi Ph.D. | Chief Science Officer |
| Ingrid Goldberg | Vice President of Investor Relations |
| Barak Ben Arye | General Counsel |
| Michael Puri | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jul 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jun 10, 2024 | 8-K | Current Report |
| May 20, 2024 | 8-K | Current Report |
| May 2, 2024 | 10-Q | Quarterly Report |
| May 2, 2024 | 8-K | Current Report |
| Apr 22, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 12, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 27, 2024 | 8-K | Current Report |